TNFRSF1B and type 1 diabetes mellitus: Screening available anti-TNFR2 monoclonal antibodies, one agonistic antibody was identified leading, e.g., in activation and expansion of Treg cells, capable of correcting type 1 diabetes-associated Treg activation defects (Okubo et al., 2013, 2016).